Serum nitrated nucleosome levels in patients with systemic lupus erythematosus: a retrospective longitudinal cohort study by Croca, S et al.
RESEARCH ARTICLE Open Access
Serum nitrated nucleosome levels in patients
with systemic lupus erythematosus: a
retrospective longitudinal cohort study
Sara Croca1*, Paul Bassett2, Charis Pericleous1, Karim Fouad Alber1, David Latchman3, David Isenberg1,4, Ian Giles1,
Anisur Rahman1 and Yiannis Ioannou1,4
Abstract
Introduction: Circulating nucleosomes released from apoptotic cells are important in the pathogenesis of systemic
lupus erythematosus (SLE). Both nucleosomes and anti-nucleosome antibodies are deposited in inflamed tissues in
patients with SLE. Active inflammation promotes nitration of tyrosine residues on serum proteins. Our hypothesis
was that levels of nitrated nucleosomes would be elevated in patients with SLE and could be associated with
disease activity. We therefore carried out a retrospective longitudinal study to investigate factors affecting levels of
nitrated nucleosomes (NN) in patients with SLE.
Methods: A novel serum ELISA was developed to measure serum NN and modified to measure serum nitrated
albumin (NA). Levels of both NN and NA were measured in 397 samples from 49 patients with SLE followed
through periods of disease flare and remission for a mean of 89 months. Anti-nucleosome antibody (anti-nuc) levels
were measured in the same samples. The effects of 24 different clinical, demographic and serological variables on
NN, NA and anti-nuc levels were assessed by univariable and multivariable analysis.
Results: Patients with SLE had higher mean NN than healthy controls or patients with other autoimmune
rheumatic diseases (P =0.01). Serum samples from 18 out of 49 (36.7%) of SLE patients were never positive for NN.
This group of 18 patients was characterized by lower anti-double stranded DNA antibodies (anti-dsDNA), disease
activity and use of immunosuppressants. In the remaining 63.3%, NN levels were variable. High NN was significantly
associated with anti-Sm antibodies, vasculitis, immunosuppressants, hydroxychloroquine and age at diagnosis. NN levels
were raised in neuropsychiatric flares. NN levels did not completely parallel NA results, thus providing additional
information over measuring nitration status alone. NN levels were not associated with anti-nuc levels.
Conclusions: NN are raised in a subset of patients with SLE, particularly those who are anti-Sm positive. Elevated NN
may be a marker of vascular activation and neuropsychiatric flares in these patients.
Introduction
Nitration and nucleosomes are both relevant to the patho-
genesis of systemic lupus erythematosus (SLE). Nitration
may be linked to development of cardiovascular disease
(CVD). Patients with SLE have an increased risk of devel-
oping CVD [1] for reasons that are not fully understood
[2,3]. Nitric oxide (NO) produced by the vascular endo-
thelium is an important metabolite involved in processes
such as vasodilatation and inhibition of platelet aggrega-
tion [4]. When produced in excess, for example under
conditions of systemic inflammation, NO can cause chem-
ical alteration of lipids and proteins. In particular, tyrosine
residues within proteins can be nitrated irreversibly, form-
ing nitrotyrosine. In patients with SLE, the serum nitrite
level (an index for NO production) correlates with disease
activity and levels of anti-double stranded DNA (anti-
dsDNA) antibodies [4]. Patients with active lupus nephritis
have higher levels of nitrotyrosine than those without
renal disease [5,6]. In theory, any serum protein contain-
ing tyrosine residues may be nitrated. We are particularly
interested in nitration of histones within nucleosomes.
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Nucleosomes are released during apoptosis and this
apoptotic debris is not cleared efficiently in patients
with SLE [7]. Both nucleosome and anti-nucleosome
antibody levels are elevated in these patients [8] and de-
position of nucleosome-anti-nucleosome complexes is
important in lupus nephritis [9]. Thus, our hypothesis is
that levels of nitrated nucleosomes (NN) in the serum
of patients with SLE could rise, particularly during flares
of disease activity. We developed a novel enzyme-linked
immunosorbent assay (ELISA) to test this hypothesis.
The principle of this novel ELISA is that serum proteins
containing nitrotyrosine residues are captured on the plate
using an anti-nitrotyrosine antibody and the subset of cap-
tured proteins that contain histones are then detected
using a polyclonal anti-histone antibody. The method de-
tects any analyte that contains both histones and nitrotyr-
osine. Since histones in serum occur primarily in the form
of nucleosomes we refer to this as a NN ELISA rather
than nitrated histone ELISA. Nucleosomes nitrated on
proteins other than histones would also be detected.
Hence, the ELISA detects the presence of nitrated tyrosine
residues upon a protein either complexed with histones or
upon core histones themselves.
We carried out measurements of NN levels in 397 sam-
ples taken from 49 patients at different time points, in-
cluding times of disease flare and remission. We carried
out univariable and multivariable analyses to determine
the demographic and clinical factors that are associated
with NN levels. We also measured levels of nitrated albu-
min (NA) as a surrogate marker of overall nitrative stress
(given that albumin is a ubiquitous protein in serum) and
the levels of anti-nucleosome antibodies (anti-nuc). Anti-
nuc levels were measured to test whether they correlate
with NN levels, which could be the case if nitration of nu-
cleosomes is important in making them more antigenic.
Methods
Patients and samples
Longitudinal serum samples (n = 397) were selected
retrospectively from a cohort of 49 patients with SLE
followed at University College London Hospital (UCLH)
with a mean of eight samples per patient (SD 2.16; min
3; max 14) and a mean follow-up of 89 months (SD 46;
min 14; max 180). All patients fulfilled the revised
American College of Rheumatology (ACR) classification
criteria for SLE [10]. We particularly selected patients
who had suffered flares of disease activity. Samples were
also obtained from 37 healthy control subjects and 38
autoimmune disease controls (13 with rheumatoid arth-
ritis, 12 with myositis and 13 with Sjogren’s syndrome).
For all SLE patient samples where data were available
(94% of samples), we obtained anti-dsDNA antibody and
complement C3 levels and disease activity from the date
of the sample and from the previous three assessments.
Anti-dsDNA antibody and C3 levels were measured in the
routine clinical laboratory at UCLH using enzyme-linked
immunosorbent assay (ELISA) (Shield Diagnostics, Dundee,
UK) and laser nephelometry, respectively. Based on the
normal limits for our laboratory, anti-dsDNA level >50
IU/ml was defined as high and C3 level <0.9 g/l as low.
Disease activity was measured using the classic British
Isles Lupus Assessment Group (BILAG) index [11]. The
more recent BILAG 2004 index was not used as many of
the samples had been taken before 2004. Current activity
(on the date of the sample) for each system was defined as
high if the BILAG score was A or B and low if it was C, D
or E. Disease activity over the most recent four assessments
was characterized as persistently low activity (if BILAG C,
D or E was recorded in all systems on each occasion) or
persistently moderate-high activity (in the presence of A
or ≥1 B score in any BILAG system on at least two out of
four occasions). Over 90% of all samples fell into one of
those two categories and the rest were excluded from this
part of the analysis.
Data on ethnicity, gender, drug therapy and anti-Sm,
anti-RNP, anti-Ro and anti-La (all tested by ELISA) anti-
body status of the patients were obtained from the clinical
records of the patients.
Ethical approval was granted by the joint UCL/UCLH
Research Ethics Committee and subjects gave informed
consent for use of their stored serum samples.
Serum assays
Capture ELISA to detect nitrated nucleosomes
The whole assay was done at room temperature (RT) ex-
cept where specified and plates were washed three to four
times with PBS-0.1% Tween (PBST) between steps. We di-
vided 96-well streptavidin plates in half: the test side was
coated with biotinylated polyclonal goat anti-nitrotyrosine
antibody (Abcam 27646, VWR Lutterworth, UK) diluted
1:1,000 in PBS and the control side coated with PBS (75
μL per well). After one hour incubation, plates were
washed and blocked with 200 μL of 0.5% ovalbumin in
PBST (OVA-BST) for one hour. After washing, serum
samples were loaded in duplicate onto the plates (100
μL/well) at 1:30 dilution in PBS such that each sample was
loaded in two wells on the test side and two matching wells
on the control side. After one hour incubation at 37°C
and washing, 50 μL per well of rabbit anti-histone H3
antibody (sc-10809, Santa Cruz Biotechnology, Santa
Cruz, CA, USA) diluted at 1:2,000 in OVA-BST were
added and the plates were incubated for one hour. After
washing, 50 μL per well of goat anti-rabbit IgG horse rad-
ish peroxidase (HRP) conjugate (Dako P0448, Dako, Ely,
UK) diluted at 1:2,000 in 0.5% OVA-BST was added. After
incubating for one hour and washing, HRP substrate was
added (100 μL per well) and incubated for 10 minutes.
The reaction was stopped with 100 μL sulphuric acid and
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optical density (OD) read at 450 nm. The net OD reading
for each sample was calculated by subtracting the OD in
the control well from that in the matching test well to ex-
clude non-specific background binding.
In order to be able to compare OD values obtained from
different plates on different days, we prepared an in-house
standard positive control sample that was loaded in serial
dilutions (range 1:15 to 1:120) on every plate. This in-
house standard was prepared by pooling serum samples
from several patients who had been found to have high
serum NN levels in this assay. The mean net OD from du-
plicate test samples was converted to absorbance units
(AU) by comparison to the standard curve of OD for the
serial dilutions of the positive control sample on each
Plate. A total of 100 AU was defined as the OD given by a
1:30 dilution of the positive control sample. The OD for
this 1:30 dilution was reproducibly high, ranging between
1.03 and 1.37.
The NN assay was reproducible with an intra and
inter-plate coefficient of variation of <10%.
Capture ELISA to detect nitrated albumin
This ELISA protocol was identical to the NN capture
ELISA with the following exceptions. The blocking agent
was 0.5% agarose in PBS and the anti-histone H3 anti-
body used was replaced with a rabbit polyclonal anti-
human albumin antibody (Abcam 2406).
Direct ELISA to detect anti-nucleosome antibodies (IgG)
All steps were carried out at 37°C. The test side of the plate
was coated with 50 μL per well of nucleosome antigen
(Arotec ATN02-02, Binding Site Ltd, Birmingham, UK) di-
luted 1:500 in 20 mM Tris/HCL buffer (pH 8.0) containing
0.15 M of NaCl; the control side was coated with buffer
alone. Incubation for two hours, then blocking with 1% bo-
vine serum albumin in PBST (BSA-PBST) for one hour were
followed by sample loading in duplicate into test and control
wells at 1:50 dilution in BSA-PBST. As the positive control, a
pooled serum sample was serially diluted (range 1:15 to
1:120) and loaded in the same way. After a 30-minute incu-
bation, goat polyclonal anti-human IgG HRP conjugate
(A6029, Sigma, Dorset, UK) diluted at 1:1,000 in BSA-PBST
was added. After incubating for 30 minutes, HRP substrate
was added and subsequent steps were as for the NN ELISA.
Statistical methods
The three outcomes in the analyses were serum NN levels,
NA levels and anti-nuc levels. All outcomes were found to
have a highly positively skewed distribution, which could
not be transformed to a more normally distributed scale.
Thus, the outcomes were assumed to follow a negative bi-
nomial distribution. Due to the longitudinal nature of the
cohort, multiple samples for each patient were considered.
To allow for the non-independence of the data, multilevel
statistical methods were used for analysis. Two level models
were used with individual measurements clustered within
patients. The analyses, performed using multilevel negative
binomial regression, were performed in two stages. First,
the separate effect of each factor upon the outcome was
examined in a series of univariable analyses. Subsequently,
the joint effect of factors was examined in a multivariable
analysis. A backward selection procedure was employed to
retain only the statistically significant variables. Variance
inflation factors were used to assess collinearity between
variables and, as a result, some variables that were collin-
ear with other variables were excluded from the multivari-
able stage of the analysis.
Additional analyses grouped patients as either NN posi-
tive or negative depending on their nitrated nucleosome
values. Variables measured at the patient level were com-
pared between groups using either Fisher’s exact test for
the categorical variables or the unpaired t-test for continu-
ous variables.
Sample level variables were analyzed using multilevel re-
gression methods to allow for the repeat measurements
from each patient. Multilevel logistic regression was used to
compare binary variables between groups, while multilevel
linear regression was used for continuous variables. Con-
tinuous variables found to have a positively skewed distri-
bution were given a log transformation before the analysis.
Results
Characteristics of subjects
The mean age of the patients with SLE at the time of
the earliest sample assayed was 36 years (SD 13.0) and
81% were female. A total of 23 were Caucasian, 18
Afro-Caribbean and 8 other ethnicities. For the healthy
controls, the mean age was 31.6 years (SD 6.0) and 62%
were female. A total of 27 were Caucasian, 1 Afro-
Caribbean and 6 other ethnicities.
Of the 49 patients with SLE, 21 were anti-Ro positive, 6
anti-La positive, 15 anti-RNP positive and 11 anti-Sm
positive. During the follow-up period, 29 patients had at
least one elevated anti-dsDNA, 32 had at least one low C3
and 46 suffered at least one flare (BILAG A or B in at least
one system). Flares in all eight systems of the classic
BILAG index were represented in the cohort.
Serum NN levels are higher in patients with SLE than in
healthy controls or patients with other
autoimmune diseases
Figure 1 shows that mean levels of serum NN in patients
with SLE were significantly higher in patients with SLE than
in healthy controls or patients with other autoimmune dis-
eases - rheumatoid arthritis, myositis or Sjogren’s syndrome
(P = 0.01 by one-way ANOVA/Kruskal Wallis test). We do
not have formal disease activity measurements for the pa-
tients with these other diseases but in most cases, samples
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were taken when patients were symptomatic. Since NN
levels were very low in 31/38 of these patients, we do
not believe that active rheumatoid arthritis, myositis or
Sjogren’s syndrome is associated with raised NN levels.
Serum NN are present in 63% of patients with SLE and
the levels of NN in these patients vary over time
Of the 49 patients with SLE tested, 18 never had detect-
able serum NN, whereas the other 31 (63%) had serum
NN levels that varied significantly over time (mean 32 AU,
SD 62.2, range 0 to 270). The characteristics of the 18
NN-negative patients and the other 31 patients are com-
pared in Table 1. All patients who never had NN were
anti-Sm negative, whereas 35% of the others were anti-Sm
positive (P = 0.004). This clear dichotomy did not apply to
any of the other antibody specificities that were tested,
though the mean anti-dsDNA level in NN-positive pa-
tients was almost twice that seen in NN-negative patients.
A total of 63.2% of NN-positive samples, but only 25.2%
of NN-negative samples, came from patients who were
taking immunosuppressants (P = 0.001).
Figure 2 shows the variation of serum NN levels over
time in five patients with SLE (patients SLE 9, 15, 18,
41 and 42) compared to variations in anti-dsDNA level
(Figures 2A-E) and global BILAG score (Figures 2F-J).
None of these patients showed close relationships be-
tween anti-dsDNA and NN over time. In some cases,
such as SLE 9, 15 18 and 42, NN levels follow disease
activity more closely than anti-dsDNA. This is espe-
cially striking in cases SLE 15 and 42, where anti-
dsDNA is always low. However, there are other cases
where the NN level is persistently low and anti-dsDNA
follows activity more closely (patient SLE 41) and it is
important to remember that approximately a third of
patients never had raised NN levels.
Clinical, demographic and serological variables associated
with serum NN and NA levels in patients with SLE
Our hypothesis was that the levels of NN in patients with
SLE would be affected both by the overall level of nitration
and by the level of serum nucleosomes present as a target
for nitration. If this were true, there should be detectable
differences between the variables influencing serum NN
levels and those influencing NA levels. These differences
clearly exist, as shown in Table 2, which includes results
from univariable analysis of 24 factors.
NN levels were twice as high in men as in women. NA
levels were five times as high in men as in women. The ef-
fects of ethnicity on NA are the opposite of the effects on
NN. Caucasians had the lowest NA levels but highest NN
levels of any ethnic group. For both NN and NA there was
a complex non-linear relationship with both disease dur-
ation and age at diagnosis. NN levels were lowest in very
young and very old subjects with a peak NN level at age
30 and at disease duration of eight years.
Anti-Sm positivity was strongly associated with both
elevated NN and elevated NA.
We did not detect any association with the commonly
used serological markers of active lupus (elevated anti-
dsDNA and low C3) or with persistent overall disease activ-
ity for either NN or NA. Considering the individual systems
of the body, we found that vasculitis flares (that is, A or B
score in the vasculitis domain of BILAG) were associated
with significantly raised serum NN and NA. NN but not
NA was raised in cardiorespiratory flares. Renal flares were
associated with a significant decrease in NA but not in NN.
There were no statistically significant differences between
flare (A/B) and non-flare (C/D/E) samples for other systems
but for neuropsychiatric flares the NN levels in C/D/E sam-
ples were approximately 50% of those in A/B samples. This
difference did not reach statistical significance due to wide
Figure 1 NN levels in patients with SLE compared to healthy and autoimmune disease controls. This figure shows the results obtained in
the NN ELISA on testing serum samples from patients with SLE in comparison with healthy controls and patients with other autoimmune
rheumatic diseases (myositis, rheumatoid arthritis and Sjogren’s syndrome). NN levels were higher in the SLE group than the other groups
(P = 0.01 by one way ANOVA/Kruskal Wallis test). NN, nitrated nucleosomes; SLE, systemic lupus erythematosus.
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confidence intervals. There was no effect of neuropsychi-
atric flares on NA levels.
Treatment with hydroxychloroquine was associated with
elevated NN and NA levels. Immunosuppressants (includ-
ing mycophenolate, azathioprine, methotrexate and cyclo-
phosphamide) were only associated with elevated NN,
whereas high dose corticosteroid treatment was associated
with neither NN nor NA.
Tables 3 and 4 show the results of multivariable analysis
of associations with NN and NA, respectively. Disease
duration, ethnicity, negative anti-La, albumin and low
renal disease activity are all associated with NA but not
NN, whereas hydroxychloroquine and high vasculitis dis-
ease activity are associated with NN but not NA. Age at
diagnosis, anti-Sm antibody positivity and treatment with
immunosuppressants all show similar associations with
both NN and NA levels. In particular, anti-Sm positivity
shows a very strong independent association with both
NN and NA (P <0.001 for both).
There is no association between serum levels of NN and
anti-nuc in multivariable analysis and different variables
are associated with these outcomes
Both univariable and multivariable analyses of the factors
associated with serum anti-nuc levels were performed.
Only the results of multivariable analysis are presented
here (in Table 5), as use of anti-nuc as a biomarker in SLE
has been studied extensively by other authors [13-15] and
is not the subject of our paper.
Samples obtained from men had higher anti-nuc levels
than samples from women. Both increasing age at diagno-
sis and increasing disease duration were associated with
significant reductions in anti-nuc levels. Increasing anti-
nuc levels were associated with elevated anti-dsDNA as
noted by previous authors [14,15] and with low C3. In con-
trast to the results obtained with NN and NA, there was no
relationship between anti-nuc and anti-Sm status. There
were no associations between treatment with hydroxychlor-
oquine or immunosuppressants and levels of anti-nuc.
Most importantly from the point of view of the present
study, there was no significant association between NN
and anti-nuc levels on multivariable analysis suggesting
that nitration probably does not affect the immunogenicity
of nucleosomes.
Discussion
In this paper we describe a novel capture ELISA that mea-
sures serum levels of NN. Mean NN levels are significantly
higher in patients with SLE than in healthy controls or in
patients with other autoimmune rheumatic diseases but
there is a subset of patients with SLE who never test posi-
tive for NN. These persistently NN-negative patients
Table 1 Comparison of patients with SLE who never had serum NN with the rest of the group
NN-negative NN-positive P-value
(n patients = 18) (n patients = 31)
(n samples = 144) (n samples = 253)
Mean age at first sample (SD)(*) 37.7 (13.1) 34.9 (12.8) 0.47
% Female (n)(*) 77.8 (14) 83.9 (26) 0.71
Ethnicity(*) 0.41
% AC (n) 27.8 (5) 41.9 (13)
% C (n) 61.1 (11) 38.7 (12)
% Other (n) 11.1 (2) 19.3 (6)
Median anti-dsDNA IU/ml (IQR)(**) (†) 29 (13, 97) 82 (17, 171) 0.18
Mean C3 g/l (SD)(**) 1.0 (0.2) 0.9 (0.3) 0.10
Median Global BILAG score (IQR)(**) (†) 5 (2, 8) 5 (3, 10) 0.22
% anti-Sm positive (n)(*) 0.0 (0) 35.5 (11) 0.004
% anti-RNP positive (n)(*) 27.8 (5) 32.3 (10) 1.00
% anti-Ro-positive (n)(*) 38.9 (7) 45.2 (14) 0.77
% anti-La positive (n)(*) 16.7 (3) 9.7 (3) 0.66
% on hydroxychloroquine (n)(**) 42.1 (61) 44.7 (113) 0.66
% on immunosuppressants (n)(**) 25.7 (37) 63.2 (160) 0.001
% on ≥5 mg/day corticosteroids (n)(**) 68.1 (98) 78.3 (198) 0.31
(*)Analysis performed at the patient level.
(**)Analysis performed at the sample level.
(†)Statistical comparison performed on log scale.
Footnote - Global BILAG score is calculated from the formula A = 9, B = 3, C = 1, D = 0, E = 0 as described in previous papers [12]. Bold type indicates statistically
significant P-values (P <0.05). BILAG, British Isles Lupus Assessment Group; NN, nitrated nucleosomes; RNP, ribonucleoprotein; SLE, systemic lupus erythematosus.
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Figure 2 Variation of NN and anti-dsDNA levels and global BILAG scores over time. This figure shows the variation of serum NN levels over
time in five patients compared to anti-dsDNA levels (A-E) and global BILAG scores (F-J). anti-dsDNA, anti-double stranded DNA antibodies; BILAG,
British Isles Lupus Assessment Group; NN, nitrated nucleosomes.
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Table 2 Univariable analysis of factors associated with serum NN and NA levels in patients with SLE
Variable Category/term Ratio for NN
(95% CI)
P-value for NN Ratio for NA
(95% CI)
P-value
for NA
Gender * Female (n = 336) 1 1
Male (n = 61) 2.01 (1.06, 3.81) 0.03 5.00 (2.50,9.98) <0.001
Disease duration† Ratio given per 5-year increase 0.43 (0.23, 0.79) 0.005 0.32 (0.20,0.51) <0.001
Age (at diagnosis)† Ratio given per 10-year increase 0.10 (0.02, 0.46) <0.001 0.04 (0.01,0.16) 0.002
Ethnicity* Caucasian (n = 182 ) 1 1
Afro-Caribbean (n = 146 ) 0.75 (0.47, 1.22) 2.07 (1.26,3.40)
Other (n = 69) 0.33 (0.17, 0.63) 0.003 3.75 (1.86,7.56) <0.001
Any ENA** No (n = 165) 1 1
Yes (n = 232) 3.43 (2.19, 5.37) <0.001 3.19 (1.93,5.27) <0.001
Anti-Ro** No (n = 226) 1 1
Yes (n = 171) 1.70 (1.12, 2.59) 0.01 1.81 (1.14,2.89) 0.01
Anti-La** No (n = 345) 1 1
Yes (n = 52) 0.79 (0.41, 1.50) 0.47 0.46 (0.20,1.06) 0.07
Anti-Sm** No (n = 298) 1 1
Yes (n = 99) 5.63 (3.66, 8.67) <0.001 6.25 (3.84,10.2) <0.001
Anti-RNP** No (n = 288) 1 1
Yes (n = 109) 1.08 (0.69, 1.70) 0.74 1.72 (1.06,2.79) 0.03
Anti-dsDNA level <50 IU/ml (n = 177) 1 1
≥50 IU/ml (n = 170) 0.76 (0.26, 1.13) 0.17 1.32 (0.66,2.65) 0.43
C3 level <0.9 g/l (n = 139) 1 1
≥0.9 g/l (n = 208) 0.83 (0.57, 1.20) 0.32 1.26 (0.86,1.87) 0.24
Disease activity in general system§ A, B (n = 31) 1 1
C, D, E (n = 344) 0.96 (0.60, 1.54) 0.87 1.19 (0.71,2.00) 0.52
Disease activity in mucocutaneous system A, B (n = 41) 1 1
C, D, E (n = 334) 0.99 (0.63, 1.56) 0.95 1.32 (0.76,2.29) 0.33
Disease activity in neuropsychiatric system A, B (n = 18) 1 1
C, D, E (n = 357) 0.56 (0.13, 2.38) 0.44 1.04 (0.50,2.19) 0.91
Disease activity in musculoskeletal system A, B (n = 47) 1 1
C, D, E (n = 328) 1.20 (0.47, 3.04) 0.71 0.68 (0.43,1.05) 0.08
Disease activity in cardiorespiratory system A, B (n = 13) 1 1
C, D, E (n = 362) 0.43 (0.24, 0.78) 0.006 1.40 (0.22,8.70) 0.72
Disease activity in vascular system A, B (n = 12) 1 1
C, D, E (n = 363) 0.33 (0.17, 0.63) 0.001 0.39 (0.19,0.82) 0.01
Disease activity in renal system A, B (n = 41) 1 1
C, D, E (n = 329) 1.09 (0.40, 2.97) 0.86 4.28 (2.13,8.58) <0.001
Disease activity in hematological system A, B (n = 95) 1 1
C, D, E (n = 280) 1.21 (0.84, 1.74) 0.30 1.44 (0.95,2.17) 0.08
Overall disease activity over last four assessments Persistently low (n = 166) 1 1
Persistently mod/high (n = 209) 0.91 (0.66, 1.25) 0.57 0.66 (0.47,0.92) 0.01
Hydroxychloroquine No (n = 223) 1 1
Yes (n = 174) 3.52 (2.40, 5.17) <0.001 3.21 (2.08,4.95) <0.001
Immunosuppression No (n = 200) 1 1
Yes (n = 197) 1.66 (1.17, 2.34) 0.004 1.33 (0.89,1.98) 0.16
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comprise about one-third of the total population and have
lower disease activity and anti-dsDNA antibody levels and
less use of immunosuppressants than the other two-thirds.
NN-negative patients are all anti-Sm antibody negative.
Currently, available serum biomarkers for monitoring
patients with SLE are antibodies (particularly anti-dsDNA)
or markers of immune activation, such as depleted com-
plement levels. Potential new serum biomarkers include
pro-inflammatory chemokines [16]. The ELISA described
in our current paper is novel in that, rather than an anti-
body or cytokine, it measures levels of an antigen, which
has been chemically modified in vivo. The critical import-
ance of nucleosomes in the pathogenesis of lupus nephritis
has been established by a number of authors. Berden and
colleagues showed that nucleosome/anti-nucleosome com-
plexes can cause nephritis in murine models of SLE [9,17].
The elegant electron microscopy studies of Rekvig’s
group demonstrated that deposited IgG co-localizes
with electron-dense chromatin structures in renal biop-
sies from human and murine lupus nephritis [18,19].
More recently, Kanapathipillai et al. showed a direct
stimulatory effect of nucleosomes alone (not requiring
complexed antibodies) on expression of chemokines by
mesangial cells from NZB/W F1 mice [20]. There is also
evidence that chemical modification of nucleosomes, spe-
cifically hyperacetylation, can alter their biological effects
in SLE. Dieker et al. demonstrated that samples from 26
of 35 patients with SLE bound more strongly to a triacety-
lated 22-amino acid peptide from histone H4 than to the
non-acetylated version of the same peptide [21]. Subcutane-
ous administration of the triacetylated, but not the non-
acetylated, peptide accelerated development of proteinuria
and increased mortality in MRL/lpr mice [21] and this effect
was not mediated via an increase in anti-nucleosome anti-
body levels. In the same paper, this group showed that
hyperacetylated nucleosomes stimulated expression of co-
stimulatory molecules and pro-inflammatory cytokines by
dendritic cells (DC) from MRL/lpr mice [21]. However, they
Table 2 Univariable analysis of factors associated with serum NN and NA levels in patients with SLE (Continued)
Oral corticosteroids ≤7.5 mg/day (n = 101) 1 1
>7.5 mg/day (n = 296) 0.81 (0.59, 1.13) 0.22 1.00 (0.69,1.44) 0.99
Albumin Ratio given per 5 g/l increase 1.38 (1.20,1.59) <0.001 1.42 (1.22,1.65) <0.001
*For gender, n values refer to the numbers of samples taken from female and male subjects, rather than the numbers of females and males in the cohort of
patients. A similar stipulation applies to ethnicity where n values refer to the number of samples taken from patients of each ethnic group.
†For the complex associations with disease duration and age, we carried out analysis of both linear and squared terms. The figures in the table refer to linear
terms. The ratios for squared terms for NN are 0.66 (95% CI: 0.51, 0.85) for disease duration and 1.56 (95% CI: 1.20, 2.03) for age. The ratios for squared terms for
NA are 0.59 (95% CI: 0.46, 0.75) for disease duration and 1.72 (95% CI: 1.32, 2.24) for age.
**For ENA, anti-Ro, anti-La and anti-Sm we did not have results from the date of every sample but it is assumed that positivity and negativity for these antigens
generally remain stable.
§“Disease activity in general system” refers to the BILAG score (A, B, C, D or E) in the General Category of the BILAG index on the day when each sample was
taken. The same principle applies to the remaining organ systems listed in the table, which are the eight different categories recorded in BILAG. Bold type
indicates statistically significant P-values (P <0.05).
Table 3 Multivariable analysis of factors associated with
serum NN levels in patients with SLE
Variable Category/term Ratio (95% CI) P-value
Age (at diagnosis) * Age 0.02 (0.003, 0.11) <0.001
Age 2.12 (1.64, 2.76)
Anti-Sm No 1
Yes 6.31 (3.39, 11.7) <0.001
Disease activity
in vascular system
A, B 1
C, D, E 0.40 (0.24, 0.69) 0.001
Hydroxychloroquine No 1
Yes 1.96 (1.09, 3.53) 0.02
Immunosuppression No 1
Yes 2.96 (1.97, 4.46) <0.001
*Ratio given for 10-year increase. NN, nitrated nucleosomes; SLE, systemic
lupus erythematosus.
Table 4 Multivariable analysis of factors associated with
serum NA levels in patients with SLE
Variable Category/term Ratio
(95% CI)
P-value
Disease duration Ratio given per
five-year increase
2.24 (1.55, 3.26) <0.001
Age (at diagnosis) * Age 0.01 (0.00, 0.04) <0.001
Age2 2.58 (1.86, 3.56)
Ethnicity Caucasian 1
Afro-Caribbean 2.99 (1.35,6.65)
Other 14.9 (5.82, 38.0) <0.001
Anti-La No 1
Yes 0.16 (0.06, 0.49) <0.001
Anti-Sm No 1
Yes 28.2 (14.4, 55.3) <0.001
Disease activity
in renal system
A, B 1
C, D, E 3.78 (2.07,6.90) <0.001
Immunosuppression No 1
Yes 1.45 (1.02, 2.05) 0.04
Albumin Ratio per 5 g/l increase 1.12 (1.01,1.24) 0.03
*Ratio given for a 10-year increase. NA, nitrated albumin; SLE, systemic
lupus erythematosus.
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did not measure levels of hyperacetylated nucleosomes in
the serum of humans or mice. Our current paper is the first
to look specifically at nitration of nucleosomes and the first
to measure serum levels of modified nucleosomes in pa-
tients with SLE. We found that elevated NN level is itself a
specific marker for SLE and is also strongly associated with
another SLE-specific biomarker in anti-Sm. Though these
are promising findings, limitations of our work include the
absence of strong association with overall disease activity
and expression of results in terms of binding of our in-
house control serum sample. If NN is to be a useful bio-
marker in patients with SLE, a more generally applicable
standard must be found. In a recently published paper,
Pratesi et al. [22] showed that sera from patients with
rheumatoid arthritis, but not from healthy controls or
patients with other autoimmune rheumatic diseases, con-
tained antibodies to deiminated histone H4. They postu-
lated that the deiminated H4 autoantigens could derive
from neutrophil extracellular traps in these patients. A
modification of our NN assay, using anti-citrulline rather
than anti-nitrotyrosine as the capture antibody, could po-
tentially be used to detect deiminated histones in the
serum of patients with rheumatoid arthritis.
There was a strong association between anti-Sm positiv-
ity and nitration in the multivariable analysis of factors as-
sociated with NN and NA levels. To our knowledge this
association between nitrative stress and anti-Sm positivity
has not been described before. The Sm antigen is a com-
plex of ribonucleoproteins in the spliceosome [23]. Anti-
Sm antibodies were first recognized in 1966 [24], and are
highly specific to patients with SLE. Anti-Sm antibodies
have been found in lupus nephritis renal biopsies [25].
Some retrospective studies reported associations between
anti-Sm positivity and psychosis [26] or nephritis [27],
while others found no association between anti-Sm anti-
bodies and any clinical outcome [28]. A large Chinese
study compared 469 anti-Sm antibody positive and 1,115
anti-Sm antibody negative patients with SLE [29]. The
anti-Sm positive patients had higher disease activity,
higher anti-dsDNA antibody and lower C3 levels than
anti-Sm negative patients. Vasculitis occurred more often
in anti-Sm positive than in anti-Sm negative patients
(13.7% vs 7.4%, P <0.05). Our current results show strong
associations among NN levels, anti-Sm and vasculitis.
Increased nitration may promote development of anti-
Sm antibodies. Experiments on mice transgenic for the
rearranged heavy chain variable region genes of a mono-
clonal anti-Sm antibody [30] showed that immature DC
carrying surface Sm antigen interacted directly with B cells
leading to the production of anti-Sm antibody. These DC
obtained Sm antigen partly from apoptotic cell debris,
which also contains nucleosomes complexed to the High
Mobility Group Box 1 (HMGB1) protein [31]. HMGB1
can activate DC [32] and also promotes NO production by
phagocytes. Thus nucleosome/HMGB1 complexes could
stimulate the DC-B cell interaction that leads to anti-Sm
antibody production as well as driving NO production. It
is not known whether nitration of HMGB1 itself alters its
pro-inflammatory properties. However, a recent study [33]
has shown that altering the redox state of HMGB1 through
the oxidation of free thiol cysteines to form disulfide bonds
makes it more pro-inflammatory. If nitration of nucleo-
some/HMGB1 complexes likewise promotes their pro-
inflammatory properties this would create a potential
positive feedback loop, and this is a mechanism that
warrants further exploration. It may also be interesting
to look at nitration of the Sm antigen.
NA and NN levels were associated with use of immuno-
suppressants. This association is unlikely to arise simply
from the fact that immunosuppressants are used more
commonly in highly active disease, because persistent clin-
ical disease activity, anti-dsDNA antibody and C3 levels
were not associated with either NA or NN levels. In future
studies it may also be interesting to look at correlations
with erythrocyte sedimentation rate and/or C-reactive
protein but we do not have data on those variables for this
study. We collected data on anti-dsDNA and C3 because
those biomarkers are more closely associated with flares in
Table 5 Multivariable analysis of factors associated with serum anti-nuc levels in patients with SLE
Variable Category/term Ratio (95% CI) P-value
Gender Female 1
Male 2.83 (1.72, 4.69) <0.001
Disease duration Ratio given per 5-year increase 0.87 (0.78, 0.98) 0.02
Age (at diagnosis) Ratio given per 10-year increase 0.59 (0.49, 0.72) <0.001
RNP No 1
Yes 0.47 (0.32, 0.70) <0.001
dsDNA Ratio given per 10-fold increase (1 unit on log scale) 1.79 (1.40, 2.28) <0.001
C3 Ratio given per 0.1 g/l increase 0.29 (0.15, 0.56) <0.001
NN level Ratio given per 10-fold increase (1 unit on log scale) 0.88 (0.72,1.07) 0.20
Anti-nuc, Anti-nucleosome antibody; dsDNA, double stranded DNA; RNP, ribonucleoprotein; SLE, systemic lupus erythematosus.
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SLE. The drugs themselves could promote nitration, but
we know of no evidence supporting this. Cyclosporin can
promote tyrosine nitration in endothelial cells [34], but
only two samples in this study were from patients taking
cyclosporin and both were negative for NN.
A large inception cohort study has shown that 40% of
1,206 patients with SLE suffered from neuropsychiatric
symptoms, which were associated with reduced quality of
life but that in the majority of cases these were not due to
active inflammation and did not require immunosuppres-
sion [35]. It is important, however, to identify the subpopu-
lation of patients in whom these symptoms are due to
active cerebral SLE. With appropriate treatment, the symp-
toms are significantly more likely to resolve in those
patients compared to patients in whom the symptoms are
not due to active SLE [35]. Current imaging techniques
and blood tests do not accurately distinguish patients
with active neuropsychiatric SLE from those who have
neuropsychiatric symptoms not caused by SLE. Our re-
sults suggesting that elevated NN levels could poten-
tially be a marker for neuropsychiatric flares are based
on results from 11 different patients taken over a 12-
year period. Over 70% of the neuropsychiatric manifes-
tations in these patients were headaches and seizures. It
is important to extend these results by testing larger
numbers of samples from patients with a wider range of
neuropsychiatric manifestations.
Vasculitis is a relatively uncommon manifestation of
SLE [29]. In multivariable analysis we found a statisti-
cally significant association of high NN (but not NA)
with vasculitis based on results from nine different
patients over an 11-year period. Review of the medical
records showed that all these patients had cutaneous
vasculitis at the time of their flares. It is possible that
raised NN levels in patients without visible vasculitis
may be a marker of subclinical vascular activation. It
will, therefore, be interesting to see whether NN levels
are associated with objective measures of atherosclerosis,
such as carotid ultrasound [2]. This potential association
is underlined by the fact that peroxynitrite, a powerful
nitrating and oxidizing agent, is generated in athero-
sclerotic plaques. If such an association exists, then NN
levels may be relevant to assessment of CVD risk in pa-
tients with SLE.
Conclusion
By developing a novel assay to measure serum NN levels
we have demonstrated that these levels are raised in pa-
tients with SLE compared to healthy controls and patients
with other autoimmune rheumatic diseases. NN-positivity
is strongly linked to anti-Sm antibody positivity and may
be a marker for neuropsychiatric flares and vasculitis in
patients with SLE. Further studies in larger numbers of pa-
tients with these manifestations are required.
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